187 related articles for article (PubMed ID: 31099446)
1. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
Takahashi M; Miki S; Fujimoto K; Fukuoka K; Matsushita Y; Maida Y; Yasukawa M; Hayashi M; Shinkyo R; Kikuchi K; Mukasa A; Nishikawa R; Tamura K; Narita Y; Hamada A; Masutomi K; Ichimura K
Cancer Sci; 2019 Jul; 110(7):2247-2257. PubMed ID: 31099446
[TBL] [Abstract][Full Text] [Related]
2. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
[TBL] [Abstract][Full Text] [Related]
3. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
[TBL] [Abstract][Full Text] [Related]
4. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
5. Eribulin shows high concentration and long retention in xenograft tumor tissues.
Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
[TBL] [Abstract][Full Text] [Related]
6. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
8. Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.
Yamaguchi S; Maida Y; Yasukawa M; Kato T; Yoshida M; Masutomi K
PLoS One; 2014; 9(11):e112438. PubMed ID: 25375122
[TBL] [Abstract][Full Text] [Related]
9. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
[TBL] [Abstract][Full Text] [Related]
10. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
Ito K; Hamamichi S; Abe T; Akagi T; Shirota H; Kawano S; Asano M; Asano O; Yokoi A; Matsui J; Umeda IO; Fujii H
Cancer Sci; 2017 Nov; 108(11):2273-2280. PubMed ID: 28869796
[TBL] [Abstract][Full Text] [Related]
12. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
[TBL] [Abstract][Full Text] [Related]
13. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
15. Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model.
Taguchi E; Horiuchi K; Senoo A; Susa M; Inoue M; Ishizaka T; Rikitake H; Matsuhashi Y; Chiba K
Biochem Biophys Res Commun; 2021 Sep; 570():89-95. PubMed ID: 34274851
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
[TBL] [Abstract][Full Text] [Related]
18. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
[TBL] [Abstract][Full Text] [Related]
19. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
20. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Tanaka S; Ishii T; Sato F; Toi M; Itou J
Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]